185 related articles for article (PubMed ID: 25428641)
1. Does vaccine-primed pancreatic cancer offer better candidates for immune-based therapies?
Zheng L
Immunotherapy; 2014; 6(10):1017-20. PubMed ID: 25428641
[No Abstract] [Full Text] [Related]
2. Immunologic approaches to the management of pancreatic cancer.
Laheru D; Biedrzycki B; Jaffee EM
Cancer J; 2001; 7(4):324-37. PubMed ID: 11561608
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.
Amedei A; Niccolai E; Prisco D
Hum Vaccin Immunother; 2014; 10(11):3354-68. PubMed ID: 25483688
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for pancreatic cancer: present and future.
Aroldi F; Zaniboni A
Immunotherapy; 2017 Jun; 9(7):607-616. PubMed ID: 28595517
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation.
Lutz ER; Wu AA; Bigelow E; Sharma R; Mo G; Soares K; Solt S; Dorman A; Wamwea A; Yager A; Laheru D; Wolfgang CL; Wang J; Hruban RH; Anders RA; Jaffee EM; Zheng L
Cancer Immunol Res; 2014 Jul; 2(7):616-31. PubMed ID: 24942756
[TBL] [Abstract][Full Text] [Related]
6. Emerging trends in the immunotherapy of pancreatic cancer.
Banerjee K; Kumar S; Ross KA; Gautam S; Poelaert B; Nasser MW; Aithal A; Bhatia R; Wannemuehler MJ; Narasimhan B; Solheim JC; Batra SK; Jain M
Cancer Lett; 2018 Mar; 417():35-46. PubMed ID: 29242097
[TBL] [Abstract][Full Text] [Related]
7. Advances in immunotherapy for pancreatic cancer: 2013.
DeVito NC; Saif MW
JOP; 2013 Jul; 14(4):347-53. PubMed ID: 23846925
[TBL] [Abstract][Full Text] [Related]
8. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors.
Soares KC; Rucki AA; Wu AA; Olino K; Xiao Q; Chai Y; Wamwea A; Bigelow E; Lutz E; Liu L; Yao S; Anders RA; Laheru D; Wolfgang CL; Edil BH; Schulick RD; Jaffee EM; Zheng L
J Immunother; 2015 Jan; 38(1):1-11. PubMed ID: 25415283
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for pancreatic ductal adenocarcinoma.
Carpenter E; Nelson S; Bednar F; Cho C; Nathan H; Sahai V; di Magliano MP; Frankel TL
J Surg Oncol; 2021 Mar; 123(3):751-759. PubMed ID: 33595893
[TBL] [Abstract][Full Text] [Related]
10. IDO1 inhibition potentiates vaccine-induced immunity against pancreatic adenocarcinoma.
Blair AB; Kleponis J; Thomas DL; Muth ST; Murphy AG; Kim V; Zheng L
J Clin Invest; 2019 Apr; 129(4):1742-1755. PubMed ID: 30747725
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy synergizes with chemotherapy targeting pancreatic cancer.
Koido S; Homma S; Takahara A; Namiki Y; Komita H; Uchiyama K; Ito M; Gong J; Ohkusa T; Tajiri H
Immunotherapy; 2012 Jan; 4(1):5-7. PubMed ID: 22149993
[No Abstract] [Full Text] [Related]
12. Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer.
Kinkead HL; Hopkins A; Lutz E; Wu AA; Yarchoan M; Cruz K; Woolman S; Vithayathil T; Glickman LH; Ndubaku CO; McWhirter SM; Dubensky TW; Armstrong TD; Jaffee EM; Zaidi N
JCI Insight; 2018 Oct; 3(20):. PubMed ID: 30333318
[TBL] [Abstract][Full Text] [Related]
13. [Current topics and future to vaccine for pancreatic cancer].
Miyazawa M; Yamaue H
Nihon Jibiinkoka Gakkai Kaiho; 2013 May; 116(5):573-80. PubMed ID: 24024272
[No Abstract] [Full Text] [Related]
14. Potential targets for pancreatic cancer immunotherapeutics.
Dodson LF; Hawkins WG; Goedegebuure P
Immunotherapy; 2011 Apr; 3(4):517-37. PubMed ID: 21463193
[TBL] [Abstract][Full Text] [Related]
15. MUCIN-4 (MUC4) is a novel tumor antigen in pancreatic cancer immunotherapy.
Gautam SK; Kumar S; Dam V; Ghersi D; Jain M; Batra SK
Semin Immunol; 2020 Feb; 47():101391. PubMed ID: 31952903
[TBL] [Abstract][Full Text] [Related]
16. Vaccine against gastrin, a polyclonal antibody stimulator, decreases pancreatic cancer metastases.
Osborne N; Sundseth R; Gay MD; Cao H; Tucker RD; Nadella S; Wang S; Liu X; Kroemer A; Sutton L; Cato A; Smith JP
Am J Physiol Gastrointest Liver Physiol; 2019 Nov; 317(5):G682-G693. PubMed ID: 31433212
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic cancer immunotherapy using a tumor lysate vaccine, engineered to express α-gal epitopes, targets pancreatic cancer stem cells.
Tanida T; Tanemura M; Miyoshi E; Nagano H; Furukawa K; Nonaka Y; Akita H; Hama N; Wada H; Kawamoto K; Kobayashi S; Eguchi H; Mori M; Doki Y
Int J Oncol; 2015 Jan; 46(1):78-90. PubMed ID: 25354268
[TBL] [Abstract][Full Text] [Related]
18. Viro-immune therapy: A new strategy for treatment of pancreatic cancer.
Ibrahim AM; Wang YH
World J Gastroenterol; 2016 Jan; 22(2):748-63. PubMed ID: 26811622
[TBL] [Abstract][Full Text] [Related]
19. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
[TBL] [Abstract][Full Text] [Related]
20. CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma.
Muth ST; Saung MT; Blair AB; Henderson MG; Thomas DL; Zheng L
Cancer Lett; 2021 Feb; 499():99-108. PubMed ID: 33271264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
